---
aliases: [WuXi Bio, 2269.HK]
---
#actor #company #biopharma #cdmo #china #public

**WuXi Biologics** (HKEX: 2269) — China-based biologics CDMO (contract development and manufacturing organization). CEO Chris Chen. Provides end-to-end biologics services from discovery to manufacturing. Part of the broader WuXi ecosystem (alongside WuXi AppTec). Under US biosecurity scrutiny — named in the BIOSECURE Act (2024) alongside WuXi AppTec, [[BGI]].

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | **2269.HK** |
| CEO | Chris Chen |
| Business | Biologics CDMO |
| Clients | Global pharma/biotech |
| Risk | US BIOSECURE Act scrutiny |
| HQ | Wuxi, Jiangsu, China |

---

## Related

- [[China]] — HQ, regulatory risk
- [[Biopharma]] — sector
- [[Qatar Economic Forum 2026]] — Chen confirmed speaker
